Immunoglobulin Patents (Class 536/23.53)
  • ANTIBODIES, VARIABLE DOMAINS & CHAINS TAILORED FOR HUMAN USE
    Publication number: 20140331343
    Abstract: The invention relates to the provision of antibody therapeutics and prophylactics that are tailored specifically for human use. The present invention provides libraries, vertebrates and cells, such as transgenic mice or rats or transgenic mouse or rat cells. Furthermore, the invention relates to methods of using the vertebrates to isolate antibodies or nucleotide sequences encoding antibodies. Antibodies, heavy chains, polypeptides, nucleotide sequences, pharmaceutical compositions and uses are also provided by the invention.
    Type: Application
    Filed: May 2, 2013
    Publication date: November 6, 2014
    Inventors: Allan Bradley, Glenn Friedrich, E-Chiang Lee, Mark Strivens, Nicholas England
  • APELIN ANTIGEN-BINDING PROTEINS AND USES THEREOF
    Publication number: 20140328850
    Abstract: This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications.
    Type: Application
    Filed: July 17, 2012
    Publication date: November 6, 2014
    Inventors: Shu-Chen Lu, Minghan Wang
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS
    Publication number: 20140329278
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: March 21, 2014
    Publication date: November 6, 2014
    Applicant: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • ANTI-INTEGRIN BETA-1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20140328830
    Abstract: The current invention provides human variable chain framework regions and humanized antibodies comprising the framework regions, the antibodies being specific for integrin ?1. The invention also provides methods for utilizing the antibodies, for example to treat diseases such as cancer.
    Type: Application
    Filed: December 24, 2013
    Publication date: November 6, 2014
    Applicant: ONCOSYNERGY, INC.
    Inventor: W. Shawn Carbonell
  • ANTI-CRTH2 ANTIBODIES AND METHODS OF USE
    Publication number: 20140328849
    Abstract: The invention provides anti-CRTh2 antibodies and methods of using the same.
    Type: Application
    Filed: March 14, 2014
    Publication date: November 6, 2014
    Applicant: GENENTECH, INC.
    Inventors: Karin REIF, Isidro HOTZEL, Jo-Anne S. HONGO, Tao HUANG, Yonglei SHANG, Meredith HAZEN
  • Cholesterol Ester Transfer Protein (CETP) Inhibitor Polypeptide Antibodies for Prophylactic and Therapeutic Anti-Atherosclerosis Treatments
    Publication number: 20140328851
    Abstract: Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 6, 2014
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Gang Ren, Lei Zhang
  • Antibodies for Molecular Imaging of Vulnerable Plaques in Atherosclerosis
    Publication number: 20140328753
    Abstract: Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient.
    Type: Application
    Filed: November 15, 2012
    Publication date: November 6, 2014
    Applicants: UNIVERSITE BORDEAUX SEGALEN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Gisele Clofent-Sanchez, Kamel Deramchia, Marie-Josee Joacobin, Stephane Bonetto, Jeanny Traineau
  • Binding members for interleukin-4 receptor alpha (IL-4R?) - 173
    Patent number: 8877189
    Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: November 4, 2014
    Assignee: MedImmune Limited
    Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
  • Polynucleotides encoding humanized anti-NGF antibodies
    Patent number: 8877491
    Abstract: Method for the humanization of the VH and VL variable regions of an animal antibody of known sequence, humanized animal antibody obtainable according to the method, in particular anti-NGF and anti-TrkA humanized animal antibodies.
    Type: Grant
    Filed: July 16, 2010
    Date of Patent: November 4, 2014
    Assignee: Abbvie Inc.
    Inventors: Antonino Cattaneo, Doriano Lamba, Sonia Covaceuszach
  • Anti-CD4 antibody
    Patent number: 8877913
    Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: November 4, 2014
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Tomoaki Nakagawa, Sayaka Hori, Rinpei Niwa, Tsuguo Kubota, Kazuhiro Masuda, Kazuyasu Nakamura
  • ANTIBODIES THAT BIND COLONY STIMULATING FACTOR 1 RECEPTOR (CSF1R)
    Publication number: 20140322757
    Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
    Type: Application
    Filed: April 30, 2014
    Publication date: October 30, 2014
    Applicant: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Justin Wong, Maximiliano Vasquez
  • Anti-FGFR2 Antibodies and Uses Thereof
    Publication number: 20140322220
    Abstract: The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use.
    Type: Application
    Filed: November 22, 2012
    Publication date: October 30, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Axel Harrenga, Charlotte Christine Kopitz, Stefanie Hammer, Frank Dittmer, Sven Golfier, Mark Trautwein, Sandra Bruder, Juergen Franz, Beatrix Stelte-Ludwig, Lars Linden, Ricarda Finnern, Simone Greven, Jan Tebbe
  • MIC-BINDING ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140322244
    Abstract: The technology described herein relates to antibodies and/or polypeptides which bind to MIC and inhibit MIC shedding. Methods of using such antibodies and/or polypeptides for the treatment of cancer are also described herein.
    Type: Application
    Filed: May 1, 2014
    Publication date: October 30, 2014
    Applicant: UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION
    Inventor: Jennifer D. Wu
  • MULTIVALENT ANTIBODIES AND USES THEREFOR
    Publication number: 20140322221
    Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.
    Type: Application
    Filed: March 28, 2014
    Publication date: October 30, 2014
    Applicant: Genentech, Inc.
    Inventors: Kathy L. MILLER, Leonard G. PRESTA
  • Antibody Constructs for CDH19 and CD3
    Publication number: 20140322218
    Abstract: The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
    Type: Application
    Filed: January 27, 2014
    Publication date: October 30, 2014
    Applicant: AMGEN RESEARCH (MUNICH) GMBH
    Inventors: Shouhua Xiao, Zheng Pan, Dineli Wickramasinghe, Shawn Jeffries, Chadwick T. King, Brian Mingtung Chan, Peter Kufer, Ralf Lutterbüse, Tobias Raum, Patrick Hoffmann, Doris Rau, Roman Kischel, Bryan Lemon, Holger Wesche
  • ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES
    Publication number: 20140322129
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: March 13, 2014
    Publication date: October 30, 2014
    Applicant: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • ANTI-IL-6 RECEPTOR ANTIBODIES AND METHODS OF USE
    Publication number: 20140322239
    Abstract: The present invention provides anti-IL-6R monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of rheumatoid arthritis and other diseases.
    Type: Application
    Filed: May 2, 2014
    Publication date: October 30, 2014
    Applicant: APEXIGEN, INC.
    Inventors: Sum Wai Pierre Lee, Yaohuang Ke, Yongke Zhang
  • NOVEL HETERODIMERIC PROTEINS
    Publication number: 20140322217
    Abstract: The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different.
    Type: Application
    Filed: January 14, 2014
    Publication date: October 30, 2014
    Applicant: Xencor, Inc.
    Inventors: Gregory MOORE, Matthew Bernett, Rumana Rashid, John Desjarlais
  • IGE ANTI-HMW-MAA Antibody
    Publication number: 20140322246
    Abstract: In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (HMW-MAA), and binding to an Fc? receptor.
    Type: Application
    Filed: October 4, 2011
    Publication date: October 30, 2014
    Applicant: KING'S COLLEGE LONDON
    Inventors: Sophia Karagiannis, Andrew Beavil, Frank Nestle
  • MONOCLONAL ANTIBODIES AGAINST SEROTRANSFERRIN ANTIGENS, AND USES THEREFOR
    Publication number: 20140322224
    Abstract: The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage prostate cancer are encompassed.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 30, 2014
    Applicant: ALPER BIOTECH LLC
    Inventor: Ozge Alper
  • ANTI-GCC ANTIBODY MOLECULES AND RELATED COMPOSITIONS AND METHODS
    Publication number: 20140322233
    Abstract: Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The antibodies bind an extracellular domain of GCC and can be internalized. In some embodiments, the antibodies are humanized, chimeric or human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Application
    Filed: June 2, 2014
    Publication date: October 30, 2014
    Inventors: Samuel S. Nam, Edward A. Greenfield, John S. Babcook, Theresa O'Keefe, Shixin Qin
  • ANTI-HUMAN ADORA2A ANTIBODIES
    Publication number: 20140322236
    Abstract: The present invention provides novel antibodies to human ADORA2A.
    Type: Application
    Filed: March 18, 2014
    Publication date: October 30, 2014
    Applicant: SDIX, LLC
    Inventors: Ross S. CHAMBERS, Michael C. BROWN, Dale V. ONISK, L. Joe STAFFORD, Fenglin YIN
  • Polynucleotides encoding antibodies that bind both IL-17A and IL-17F
    Patent number: 8871467
    Abstract: The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, hybridomas that produce the antibodies, and methods of using the same in inflammation.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 28, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Stephen R. Jaspers, Scott R. Presnell, Monica J. Huber
  • Neutralizing anti-influenza A virus antibodies and uses thereof
    Patent number: 8871207
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that specifically bind to an epitope in the stem region of an influenza A hemagglutinin trimer and neutralize a group 1 subtype and a group 2 subtype of influenza A virus. The invention also relates to nucleic acids that encode, immortalized B cells and cultured single plasma cells that produce, and to epitopes that bind to such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and epitopes in screening methods as well as in the diagnosis, treatment and prevention of influenza A virus infection.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: Humabs, LLC
    Inventor: Antonio Lanzavecchia
  • LUNG-TARGETING NANOBODIES AGAINST PULMONARY SURFACTANT PROTEIN A AND THEIR PREPARATION
    Publication number: 20140314832
    Abstract: The present invention relates to pharmaceutical and medical technologies, and more particularly to novel nanobodies against pulmonary surfactant protein A (SP-A) and their preparation methods. The nanobodies of the present invention comprises an amino acid sequence having certain formula. The present invention also relates to nucleic acid sequences encoding the nanobodies, their preparation method and their applications. Immunohistochemistry and in vivo imaging show that the nanobodies of the present inventions have high lung-targeting specificity.
    Type: Application
    Filed: August 2, 2013
    Publication date: October 23, 2014
    Applicant: Shanghai Pulmonary Hospital, Tongji University School of Medicine
    Inventors: Huiping Li, Shanmei Wang
  • Interleukin-31 Monoclonal Antibody
    Publication number: 20140315251
    Abstract: An isolated antibody that specifically binds to at least one of canine Interleukin-31 (IL-31) or feline IL-31 is provided. Such antibodies can be in the form of diagnostic and/or veterinary compositions useful for treating a pruritic and/or allergic condition in dogs or cats.
    Type: Application
    Filed: July 8, 2014
    Publication date: October 23, 2014
    Inventors: Gary F. Bammert, Steven A. Dunham
  • HUMANIZED ANTIBODIES AGAINST TL1A
    Publication number: 20140315250
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 23, 2014
    Applicant: TEVA Biopharmaceuticals USA, Inc.
    Inventors: Rodger SMITH, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • ENDOGLIN ANTIBODIES
    Publication number: 20140314742
    Abstract: The present application relates to compositions of humanized and humanized/deimmunized anti-endoglin antibodies and antigen-binding fragments thereof. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both. Another aspect relates to antibodies which bind endoglin and inhibit angiogenesis. Another aspect relates to the deimmunization of humanized antibodies to reduce immunogenicity. Another aspect relates to the use of humanized and humanized/deimmunized antibodies which bind endoglin for the detection, diagnosis or treatment of a disease or condition associated with endoglin, angiogenesis or a combination thereof.
    Type: Application
    Filed: October 15, 2013
    Publication date: October 23, 2014
    Applicant: TRACON PHARMACEUTICALS, INC.
    Inventors: Charles Theuer, Maximiliano Vasquez
  • CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES
    Publication number: 20140314763
    Abstract: The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.
    Type: Application
    Filed: January 6, 2014
    Publication date: October 23, 2014
    Applicant: Genentech, Inc.
    Inventors: Yongmei Chen, Yan (Helen) Hu, Wenjun Ouyang, Scott Stawicki, Yan Wu
  • ANTI-CXCR4 ANTIBODIES AND METHODS OF USE
    Publication number: 20140314784
    Abstract: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.
    Type: Application
    Filed: July 19, 2012
    Publication date: October 23, 2014
    Applicant: Medlmmune Limited
    Inventors: Vahe Bedian, Youzhen Wang, Ian Foltz, Palaniswami Rathanaswami, Jaspal Singh Kang, Adeela Kamal, Philipp Steiner
  • BIOLOGICAL MATERIALS AND USES THEREOF
    Publication number: 20140314793
    Abstract: The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce cell death of the target cell. There is also provided methods of and pharmaceutical compositions for cell death induction and uses thereof.
    Type: Application
    Filed: April 11, 2014
    Publication date: October 23, 2014
    Applicant: BIOINVENT INTERNATIONAL AB
    Inventors: Björn Frendéus, Roland Carlsson, Ingrid Teige, Linda Mårtensson
  • Fusion polypeptides capable of activating receptors
    Patent number: 8865430
    Abstract: A fusion polypeptide comprising (A)x-M-(A?)y, wherein A and A? are each polypeptides capable of binding a target receptor. The fusion polypeptides of the invention form multimeric proteins which activate the target receptor. A and A? may be each be an antibody or fragment derived from an antibody specific for a target receptor, such as the same or different scFv fragments, and/or a ligand or ligand fragment or derivative capable of binding the target protein, M is a multimerizing component, and X and Y are independently a number between 1-10.
    Type: Grant
    Filed: May 13, 2013
    Date of Patent: October 21, 2014
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: James P. Fandl, Gang Chen, Nicholas J. Papadopoulos, Thomas H. Aldrich
  • ANTIBODIES DIRECTED AGAINST THE ALPHA CHAIN OF IL7 RECEPTOR - THEIR USE FOR THE PREPARATION OF DRUG CANDIDATES
    Publication number: 20140308281
    Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.
    Type: Application
    Filed: October 4, 2012
    Publication date: October 16, 2014
    Inventors: Sophie Brouard, Le Hoa Mai, Caroline Mary, Nicolas Poirier, Jean-Paul Soulillou, Bernard Vanhove
  • BMP-6 Antibodies
    Publication number: 20140309404
    Abstract: The present invention relates to antibodies, or antigen-binding fragments thereof, that bind to human BMP-6, compositions comprising such antibodies, or antigen-binding fragments thereof, and methods of using the same for treatment of anemia of chronic disease.
    Type: Application
    Filed: June 26, 2014
    Publication date: October 16, 2014
    Inventors: Neungseon Steven Seo, Stephanie Marie Eaton Truhlar
  • HETERODIMERIC BISPECIFIC ANTIBODIES
    Publication number: 20140308285
    Abstract: Provided herein are heterodimeric bispecific antibodies that can mediate cytolysis of a target cell by an immune effector cell, nucleic acids encoding such antibodies, methods of making such antibodies, and methods of using such antibodies. These antibodies comprise two different polypeptide chains, each comprising two immunoglobulin variable regions and, optionally, a half life-extending moiety.
    Type: Application
    Filed: March 12, 2014
    Publication date: October 16, 2014
    Applicant: Amgen Inc.
    Inventors: Wei YAN, Martin J. PENTONY, Luis G. BORGES, Mark L. MICHAELS
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20140308206
    Abstract: The disclosure relates to antibodies that bind FcRn and methods of using these antibodies.
    Type: Application
    Filed: June 1, 2012
    Publication date: October 16, 2014
    Applicant: DYAX CORP.
    Inventors: Daniel J. Sexton, Christopher Tenhoor, Malini Viswanathan
  • ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME
    Publication number: 20140308276
    Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.
    Type: Application
    Filed: February 9, 2012
    Publication date: October 16, 2014
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Yong-Jun Liu, Kui Shin Voo, Laura Bover, Naoya Tsurushita, J. Yun Tso, Shankar Kumar
  • HUMANIZED ANTIBODIES
    Publication number: 20140308269
    Abstract: Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID NO:25 and 27 (HumG); SEQ ID NO:29 and 31 (HumH); and SEQ ID NO:33 and 35 (HumI). Subsequences of the humanized antibodies capable of finding an ICAM-1 epitope are also provided. Methods of inhibiting pathogen infection (e.g., HRV) of a cell employing humanized antibodies capable of finding an ICAM-1 epitope are further provided.
    Type: Application
    Filed: November 18, 2013
    Publication date: October 16, 2014
    Applicant: Perlan Therapeutics, Inc.
    Inventors: Fang FANG, Lori Kohlstaedt, John Reno
  • ANTI-5T4 ANTIBODIES AND USES THEREOF
    Publication number: 20140308302
    Abstract: Anti-5T4 antibodies, anti-5T4 antibody/drug conjugates, and methods for preparing and using the same.
    Type: Application
    Filed: May 29, 2014
    Publication date: October 16, 2014
    Inventors: Erwin R. BOGHAERT, Nitin K. DAMLE, Philip Ross HAMANN, Kiran KHANDKE, Arthur KUNZ, Kimberly A. MARQUETTE, Lioudmila TCHISTIAKOVA, Davinder GILL, Kodangattil R. SREEKUMAR
  • ANTIBODY DRUG CONJUGATES
    Publication number: 20140308201
    Abstract: The present invention relates to anti-FGFR2 antibodies, antibody fragments, antibody drug conjugates, and their uses for the treatment of cancer.
    Type: Application
    Filed: March 11, 2014
    Publication date: October 16, 2014
    Applicant: NOVARTIS AG
    Inventors: David Bryant BATT, Seth Alexander Ettenberg, Nicole Haubst, Tiancen Hu, David Jenkins, Engin Toksoz, Konstantin Petropoulos, Matthew John Meyer
  • DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20140308286
    Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
    Type: Application
    Filed: March 19, 2014
    Publication date: October 16, 2014
    Applicant: AbbVie Inc.
    Inventors: Tariq Ghayur, Jochen G. Salfeld, Michael J. McPherson, Maria C. Harris, Junjian Liu, Peter C. Isakson, Jijie Gu
  • CD44 MONOCLONAL ANTIBODY FOR THE TREATMENT OF B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA AND OTHER HEMATOLOGICAL MALIGNANCIES
    Publication number: 20140308301
    Abstract: Compositions including an antibody specific for CD44 are provided. These antibodies specifically bind to hematologic malignant cells. Methods to use the CD44 antibodies to target cells expressing CD44 for therapeutic and diagnostic purposes are also provided.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 16, 2014
    Inventors: Thomas J. Kipps, Suping Zhang, Christina C. Wu
  • ANTIBODIES THAT BIND TO TL1A AND THEIR USES
    Publication number: 20140308271
    Abstract: The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 52, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 56.
    Type: Application
    Filed: January 2, 2014
    Publication date: October 16, 2014
    Applicant: GLENMARK PHARMACEUTICALS S.A.
    Inventors: ANTOINE ATTINGER, JONATHAN ALBERT BACK, STANISLAS BLEIN, RAMI LISSILAA, DARKO SKEGRO
  • Antibodies Directed to Angiopoietin-like Protein 4 and Uses Thereof
    Publication number: 20140302055
    Abstract: Antibodies directed to the antigen ANGPTL4 and uses of such antibodies. In accordance with the teachings herein, there are provided fully human monoclonal antibodies directed to the antigen ANGPTL4. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Application
    Filed: October 15, 2012
    Publication date: October 9, 2014
    Inventors: Haihong Zhong, Qing Zhou
  • PRODUCTION OF HETERODIMERIC PROTEINS
    Publication number: 20140303356
    Abstract: The present invention relates to an in vitro method for production of heterodimeric proteins.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 9, 2014
    Applicants: GENMAB A/S
    Inventors: Michael Gramer, Amitava Kundu, Ewald T. J. Van Den Bremer, Muriel Van Kamper, Patrick Priem, Aran Frank Labrijn, Joyce I. Meesters, Joost J. Neijssen, Janine Schuurman, Paul Parren, Patrick Van Berkel, Werner L. Vos, Arnout Gerritsen
  • HUMAN ANTI IL-6 ANTIBODIES WITH EXTENDED IN VIVO HALF-LIFE AND THEIR USE IN TREATMENT OF ONCOLOGY, AUTOIMMUNE DISEASES AND INFLAMMATORY DISEASES
    Publication number: 20140302058
    Abstract: The present invention provides human anti-IL-6 antibodies with extended in vivo half-life. The invention further relates to pharmaceutical compositions, therapeutic compositions, and methods using therapeutic antibodies that bind to IL-6 and that has an extended in vivo half-life for the treatment and prevention of IL-6 mediated diseases and disorders, such as, but not limited to, inflammatory diseases and disorders, autoimmune diseases and disorders and tumors.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 9, 2014
    Applicant: MedImmune, LLC
    Inventors: Michael Bowen, Herren Wu, William Dall'Acqua, Peter Kiener, Bahija Jallal, Anthony Coyle
  • HUMAN ANTIBODIES SPECIFICALLY BINDING TO THE HEPATITIS B VIRUS SURFACE ANTIGEN
    Publication number: 20140302598
    Abstract: Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B.
    Type: Application
    Filed: May 21, 2014
    Publication date: October 9, 2014
    Inventors: Se-Ho KIM, Ki Hwan CHANG, Kwang-Won HONG, Yong-Won SHIN, Min-soo KIM, Hae-Won LEE, Kyung Hwan RYOO, Dong Hyuck SEO, Jean Man KIM, Yong Nam SHIN, Sunmi KOO, Jung-Ae LIM, Mijung LEE, Yeon Kyung LEE, Misun SEO
  • ALBUMIN BINDING ANTIBODIES AND BINDING FRAGMENTS THEREOF
    Publication number: 20140302033
    Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
    Type: Application
    Filed: November 9, 2012
    Publication date: October 9, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: Ralph Adams, Pavalli Bhatta, Sam Phillip Heywood, David Paul Humphreys
  • ANTI-AXL ANTIBODIES AND USES THEREOF
    Publication number: 20140302041
    Abstract: The present invention relates to anti-Axl antibodies and uses thereof in diagnostic and therapeutic methods. More particularly, the present invention relates to a monoclonal antibody having specificity for Axl comprising an heavy chain variable region comprising SEQ ID NO:2 in the H-CDR1 region, SEQ ID NO:3 in the H-CDR2 region and SEQ ID NO:4 in the H-CDR3 region; and a light chain variable region comprising SEQ ID NO: 6 in the L-CDR1 region, SEQ ID NO:7 in the L-CDR2 region and SEQ ID NO:8 in the L-CDR3 region. Said monoclonal antibody binds to the extracellular domain of Axl via, SEQ ID NO:9, SEQ ID NO: 10 and SEQ ID NO: 11.
    Type: Application
    Filed: June 22, 2012
    Publication date: October 9, 2014
    Applicants: ORIBASE PHARMA, Institut Regional du Cancer de Montpellier-Val d' Aurelle, INSERM (Institut National de la Sante et de la Recherche Medicale), UNIVERSITE DE MONTPELLIER 1
    Inventors: Bruno Robert, Benedicte Fauvel, Gwenael Cheve, Aziz Yasri, Christel Larbouret, Wilhem Leconet, Thierry Chardes, Christian Larroque, Andre Pelegrin
  • BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF
    Publication number: 20140302016
    Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: LINDA C. BURKLY, JANINE L. FERRANT-ORGETTAS, ELLEN A. GARBER, YEN-MING HSU, LIHE SU, FREDERICK R. TAYLOR, RALPH ADAMS, DEREK THOMAS BROWN, ANDREW GEORGE POPPLEWELL, MARTYN KIM ROBINSON, ANTHONY SHOCK, KERRY LOUISE TYSON